Management of Systemic Autoimmune Rheumatic Disease-Associated Interstitial Lung Disease

First-Line Treatment Options

The American College of Rheumatology recommends mycophenolate as the preferred first-line therapy across all SARD-ILD subtypes, with a conditional recommendation 1, 2, 3
Azathioprine is a conditionally recommended alternative first-line option for many SARD-ILD subtypes, except systemic sclerosis (SSc), according to the American College of Rheumatology 2, 4
Rituximab is conditionally recommended across all SARD-ILD subtypes, as stated by the American College of Rheumatology 1, 4
Cyclophosphamide is conditionally recommended as an additional option for most SARD-ILD subtypes, according to the American College of Rheumatology 1, 3

For SSc-ILD, the American College of Rheumatology conditionally recommends tocilizumab and nintedanib as first-line options 4, 3
For idiopathic inflammatory myopathy (IIM)-ILD, the American College of Rheumatology conditionally recommends JAK inhibitors and calcineurin inhibitors (CNIs) 4, 5
For rheumatoid arthritis (RA)-ILD, there is no consensus on nintedanib as first-line therapy, as stated by the American College of Rheumatology 3

The American College of Rheumatology conditionally recommends mycophenolate, rituximab, cyclophosphamide, and nintedanib as treatment options for patients showing progression despite first-line therapy 1, 2
Long-term glucocorticoids are strongly recommended against in SSc-ILD and conditionally recommended against in other SARD-ILD subtypes, according to the American College of Rheumatology 1, 6
For RA-ILD progression, the American College of Rheumatology conditionally recommends adding pirfenidone 1
For SSc-ILD, MCTD-ILD, or RA-ILD progression, the American College of Rheumatology conditionally recommends tocilizumab 1, 3
For IIM-ILD progression, the American College of Rheumatology conditionally recommends calcineurin inhibitors and JAK inhibitors 1, 5
For SSc-ILD progression, the American College of Rheumatology conditionally recommends referral for stem cell transplantation and/or lung transplantation 1, 5

The American College of Rheumatology conditionally recommends pulse intravenous methylprednisolone as first-line treatment for RP-ILD 1, 5
Rituximab, cyclophosphamide, IVIG, mycophenolate, CNIs, and JAK inhibitors are conditionally recommended as first-line options for RP-ILD, according to the American College of Rheumatology 1, 5
Upfront combination therapy is conditionally recommended over monotherapy for RP-ILD, as stated by the American College of Rheumatology 2, 5
Early referral for lung transplantation is conditionally recommended over later referral for RP-ILD, according to the American College of Rheumatology 1, 5

The American College of Rheumatology recommends avoiding glucocorticoids in SSc-ILD patients due to the risk of scleroderma renal crisis, particularly at doses >15mg/day of prednisone equivalent 6, 3
Treatment decisions should consider disease subtype, severity, progression rate, and fibrotic pattern on imaging, as stated by the American College of Rheumatology 2, 3
Cyclophosphamide is typically not used in combination with other therapies, unlike other agents which may be used individually or in combination, according to the American College of Rheumatology 2
Early recognition and treatment are crucial, as many forms of ILD can progress to irreversible fibrosis if not managed appropriately, as stated by the American College of Rheumatology and the European League Against Rheumatism 7

CRP elevation indicates inflammatory phase disease requiring anti-inflammatory treatment rather than observation alone 8
Tocilizumab demonstrates particular efficacy in MCTD patients with elevated CRP, progressive skin thickening, and early diffuse disease 9
CRP levels correlate with disease activity and can guide treatment intensity, with significant declines indicating therapeutic response 10, 11

The American College of Rheumatology conditionally recommends mycophenolate as first-line therapy for MCTD-ILD 9
Mycophenolate is the preferred first-line agent across all MCTD presentations, effective for both pulmonary and systemic manifestations 9

Expect CRP normalization within 3-6 months of appropriate immunosuppression, with persistent CRP elevation indicating inadequate disease control 10, 11
ILD can progress asymptomatically to irreversible fibrosis, and elevated CRP may indicate subclinical pulmonary inflammation 12, 13

Do not delay immunosuppression while waiting for complete diagnostic workup—early treatment prevents irreversible organ damage 12, 13
Do not use long-term high-dose glucocorticoids as monotherapy—this increases mortality risk without addressing underlying pathophysiology 9